Search Results - (Author, Cooperation:R. Peeling)
-
1Latest Papers from Table of Contents or Articles in PressA. Phillips ; A. Shroufi ; L. Vojnov ; J. Cohn ; T. Roberts ; T. Ellman ; K. Bonner ; C. Rousseau ; G. Garnett ; V. Cambiano ; F. Nakagawa ; D. Ford ; L. Bansi-Matharu ; A. Miners ; J. D. Lundgren ; J. W. Eaton ; R. Parkes-Ratanshi ; Z. Katz ; D. Maman ; N. Ford ; M. Vitoria ; M. Doherty ; D. Dowdy ; B. Nichols ; M. Murtagh ; M. Wareham ; K. M. Palamountain ; C. Chakanyuka Musanhu ; W. Stevens ; D. Katzenstein ; A. Ciaranello ; R. Barnabas ; R. S. Braithwaite ; E. Bendavid ; K. J. Nathoo ; D. van de Vijver ; D. P. Wilson ; C. Holmes ; A. Bershteyn ; S. Walker ; E. Raizes ; I. Jani ; L. J. Nelson ; R. Peeling ; F. Terris-Prestholt ; J. Murungu ; T. Mutasa-Apollo ; T. B. Hallett ; P. Revill
Nature Publishing Group (NPG)
Published 2015Staff ViewPublication Date: 2015-12-04Publisher: Nature Publishing Group (NPG)Print ISSN: 0028-0836Electronic ISSN: 1476-4687Topics: BiologyChemistry and PharmacologyMedicineNatural Sciences in GeneralPhysicsKeywords: Adolescent ; Adult ; Africa ; Aged ; Anti-HIV Agents/economics/pharmacology/therapeutic use ; Cost-Benefit Analysis ; HIV Infections/diagnosis/*drug therapy/economics/*virology ; Humans ; Middle Aged ; Precision Medicine/economics/*methods ; *Viral Load/drug effects ; Young AdultPublished by: -
2Latest Papers from Table of Contents or Articles in PressStaff View
Publication Date: 2018-03-14Publisher: Oxford University PressPrint ISSN: 0022-1899Electronic ISSN: 1537-6613Topics: MedicinePublished by: -
3Articles: DFG German National LicensesStaff View
ISSN: 1435-4373Source: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Abstract Some of the newer fluoroquinolones may be suitable agents for the treatment ofChlamydia trachomatis infections and non-gonococcal urethritis. To date, small studies with both ofloxacin and fleroxacin appear to achieve cure rates of 85–100% for urethritis and cervicitis due toChlamydia trachomatis. However, large well-designed clinical trials are required to determine the efficacy and acceptance of these and other fluoroquinolones in the treatment of patients with genital or respiratory syndromes due to chlamydiae or other bacterial pathogens causing infections with similar manifestations.Type of Medium: Electronic ResourceURL: